Major NHS Order

Deltex Medical Group PLC
18 March 2005

                            Deltex Medical Group plc

                      Major Order Received from NHS Trust

18 March 2005 - Deltex Medical Group plc ('Deltex Medical' or 'Company') today
announces the receipt of its first major order of 2005 from an NHS Trust to
implement the Company's CardioQTM system as a standard of care in moderate and
major risk surgery.

Birmingham Heartlands and Solihull NHS Trust (Teaching), which runs the
Birmingham Heartlands and Solihull hospitals, has placed an order with the
Company for a total of 8 CardioQ monitors to be installed in operating theatres
across the two sites, together with sufficient probes for initial training. The
Trust's internal business case was approved on the basis of it using up to 250
probes per month by the end of this first phase of wide-scale implementation of
the CardioQ.

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

Andy Hill, Deltex Medical's Chief Executive, said: 'Birmingham Heartlands and
Solihull are the first UK NHS hospitals to place wide-scale orders for CardioQ
equipment in 2005.  We will be working closely with the hospitals over the
coming months to help them maximise both the clinical and economic benefits of
the CardioQ.  In the meantime, our discussions continue with other NHS trusts
regarding implementation of the CardioQ and we expect to announce further orders
as these discussions progress.'


For further information, please contact:-

Deltex Medical Group plc                             01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics
David Yates/Lucy Briggs                              0207 831 3113



Notes for Editors

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works


  • proved that the CardioQ works in a wide range of surgical procedures


  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.





                      This information is provided by RNS
            The company news service from the London Stock Exchange                  EID